EX-4.2
from 6-K
7 pages
Third Supplemental Indenture Dated as of May 15, 2018, Among Glaxosmithkline Capital Inc., a Corporation Organized Under the Laws of the State of Delaware (The “Company”), Glaxosmithkline plc, a Public Limited Company Incorporated Under the Laws of England and Wales, as Guarantor (The “Guarantor”), and Deutsche Bank Trust Company Americas, a New York Banking Corporation Duly Organized and Existing Under the Laws of New York (The “Trustee”) (As Successor to Law Debenture Trust Company of New York, (The “Former Trustee”) Which Was a Successor to Citibank, N.A. (The “Original Trustee” ))
12/34/56
EX-4.1
from 6-K
6 pages
Second Supplemental Indenture Dated as of May 15, 2018, Among Glaxosmithkline Capital PLC, a Public Limited Company Incorporated Under the Laws of England and Wales (The “Company”), Glaxosmithkline plc, a Public Limited Company Incorporated Under the Laws of England and Wales, as Guarantor (The “Guarantor”), and Deutsche Bank Trust Company Americas, a New York Banking Corporation Duly Organized and Existing Under the Laws of New York (The “Trustee”) (As Successor to Law Debenture Trust Company of New York, (The “Former Trustee”) Which Was a Successor to Citibank, N.A. (The “Original Trustee” )
12/34/56
EX-4.7
from F-3
8 pages
First Supplemental Indenture Dated as of March 21, 2014, Among Glaxosmithkline Capital PLC, a Public Limited Company Incorporated Under the Laws of England and Wales (The “Company”), Glaxosmithkline plc, a Public Limited Company Incorporated Under the Laws of England and Wales, as Guarantor (The “Guarantor”), and Law Debenture Trust Company of New York (As Successor to Citibank, N.A.), a Company Duly Organized and Existing Under the Laws of the State of New York (The “Trustee”)
12/34/56
EX-4.5
from F-3
7 pages
Second Supplemental Indenture Dated as of March 21, 2014, Among Glaxosmithkline Capital Inc., a Corporation Organized Under the Laws of the State of Delaware (The “Company”), Glaxosmithkline plc, a Public Limited Company Incorporated Under the Laws of England and Wales, as Guarantor (The “Guarantor”), and Law Debenture Trust Company of New York (As Successor to Citibank, N.A.), a Company Duly Organized and Existing Under the Laws of the State of New York (The “Trustee”)
12/34/56
EX-4.7
from F-3ASR
8 pages
First Supplemental Indenture Dated as of March 21, 2014, Among Glaxosmithkline Capital PLC, a Public Limited Company Incorporated Under the Laws of England and Wales (The “Company”), Glaxosmithkline plc, a Public Limited Company Incorporated Under the Laws of England and Wales, as Guarantor (The “Guarantor”), and Law Debenture Trust Company of New York (As Successor to Citibank, N.A.), a Company Duly Organized and Existing Under the Laws of the State of New York (The “Trustee”)
12/34/56
EX-4.5
from F-3ASR
7 pages
Second Supplemental Indenture Dated as of March 21, 2014, Among Glaxosmithkline Capital Inc., a Corporation Organized Under the Laws of the State of Delaware (The “Company”), Glaxosmithkline plc, a Public Limited Company Incorporated Under the Laws of England and Wales, as Guarantor (The “Guarantor”), and Law Debenture Trust Company of New York (As Successor to Citibank, N.A.), a Company Duly Organized and Existing Under the Laws of the State of New York (The “Trustee”)
12/34/56
EX-4.1
from 6-K
7 pages
First Supplemental Indenture Dated as of March 18, 2013, Among Glaxosmithkline Capital Inc., a Corporation Organized Under the Laws of the State of Delaware (The “Company”), Glaxosmithkline plc, a Public Limited Company Incorporated Under the Laws of England and Wales, as Guarantor (The “Guarantor”), and Law Debenture Trust Company of New York (As Successor to Citibank, N.A.), a Company Duly Organized and Existing Under the Laws of the State of New York (The “Trustee”)
12/34/56
